Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
Open accessAbstract
Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have an inherent tendency to progress to acute myeloid leukemia (AML). Using high‐resolution SNP microarrays, we studied a total of 517 MPN and MDS patients in different disease stages, including 77 AML cases with previous history of MPN (N = 46) or MDS (N = 31). Frequent chromosomal deletions of variable sizes were detected, allowing the mapping of putative tumor suppressor genes involved in the leukemic transformation process. We detected frequent deletions on the short arm of chromosome 6 (del6p). The common deleted region on 6p mapped to a 1.1‐Mb region and contained only the JARID2 gene—member of the polycomb repressive complex 2 (PRC2). When we compared the frequency of del6p between chronic and leukemic phase, we observed a strong association of del6p with leukemic transformation (P = 0.0033). Subsequently, analysis of deletion profiles of other PRC2 members revealed frequent losses of genes such as EZH2, AEBP2, and SUZ12; however, the deletions targeting these genes were large. We also identified two patients with homozygous losses of JARID2 and AEBP2. We observed frequent codeletion of AEBP2 and ETV6, and similarly, SUZ12 and NF1. Using next generation exome sequencing of 40 patients, we identified only one somatic mutation in the PRC2 complex member SUZ12. As the frequency of point mutations in PRC2 members was found to be low, deletions were the main type of lesions targeting PRC2 complex members. Our study suggests an essential role of the PRC2 complex in the leukemic transformation of chronic myeloid disorders. Am. J. Hematol. 2012. © 2011 Wiley Periodicals, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Loss-of-function mutations in other core PRC2 components EED and SUZ12 are seen in T-cell acute lymphoblastic leukaemia and malignant peripheral nerve sheath tumours.
“Loss-of-function mutations in other core PRC2 components EED and SUZ12 are also seen in T-cell acute lymphoblastic leukaemia and malignant peripheral nerve sheath tumours 153-155 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · see citing works
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · see citing works
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,518 · see citing works
Mutation in <i>TET2</i> in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · see citing works
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · see citing works
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · see citing works
Shen, X., Liu, Y., Hsu, Y.-J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.-C., & Orkin, S. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.016 · Cited by 1,021 · see citing works
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity
Pasini, D., Bracken, A. P., Jensen, M. R., Denchi, E. L., & Helin, K. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600402 · Cited by 910 · see citing works
The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development
O’Carroll, D., Erhardt, S., Pagani, M., Barton, S. C., Surani, M. A., & Jenuwein, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4330-4336.2001 · Cited by 908 · see citing works
Cao, R., & Zhang, Y. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.020 · Cited by 809 · see citing works
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 754 · see citing works
JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells
Pasini, D., Cloos, P. A., Walfridsson, J., Olsson, L., Bukowski, J., Johansen, J. V., Bak, M., Tommerup, N., Rappsilber, J., & Helin, K. (2010) · Nature · doi:10.1038/nature08788 · Cited by 562 · see citing works
Peng, J. C., Valouev, A., Swigut, T., Zhang, J., Zhao, Y., Sidow, A., & Wysocka, J. (2009) · Cell · doi:10.1016/j.cell.2009.12.002 · Cited by 533 · see citing works
Jarid2 and PRC2, partners in regulating gene expressionPreprint
Li, G., Margueron, R., Ku, M., Chambon, P., Bernstein, B., & Reinberg, D. (2010) · Genes & Development · doi:10.1101/gad.1886410 · Cited by 499 · see citing works
Tefferi, A., Pardanani, A., Lim, K., Abdel-Wahab, O., Lasho, T., Patel, J., Gangat, N., Finke, C., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 441 · see citing works
The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion
Kamminga, L. M., Bystrykh, L. V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B., & de Haan, G. (2006) · Blood · doi:10.1182/blood-2005-09-3585 · Cited by 376 · see citing works
The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation
Montgomery, N. D., Yee, D., Chen, A., Kalantry, S., Chamberlain, S. J., Otte, A. P., & Magnuson, T. (2005) · Current Biology · doi:10.1016/j.cub.2005.04.051 · Cited by 345 · see citing works
Abdel-Wahab, O. I., Manshouri, T., Patel, J. L., Harris, K., Yao, J., Hedvat, C. V., Heguy, A., Bueso-Ramos, C., Kantarjian, H. M., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 325 · see citing works
Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm
Beer, P. A., Delhommeau, F., Couedic, J. P. L., Dawson, M. A., Chen, E., Bareford, D., Kušec, R., McMullin, M. F., Harrison, C. N., Vannucchi, A. M., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236596 · Cited by 306 · see citing works
Self-citationEzh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo
Sarma, K., Margueron, R., Ivanov, A. V., Pirrotta, V., & Reinberg, D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02017-07 · Cited by 286 · see citing works
Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A. R., & Beer, P. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285 · see citing works
Banham, A. H., Beasley, N. J. P., Campo, E., Fernández, P. L., Fidler, C., Gatter, K. C., Jones, M. M., Mason, D. Y., Prime, J. E., Trougouboff, P., et al. (2001) · PubMed · Cited by 253 · see citing works
Sewalt, R. G. A. B., van der Vlag, J., Gunster, M. J., Hamer, K. M., den Blaauwen, J. L., Satijn, D. P. E., Hendrix, T., DRIEL, R. V., & Otte, A. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3586 · Cited by 221 · see citing works
Functional antagonism of the polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation
Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., & Sauvageau, G. (1999) · Genes & Development · doi:10.1101/gad.13.20.2691 · Cited by 219 · see citing works
p53 Lesions in Leukemic Transformation
Harutyunyan, A. S., Klampfl, T., Cazzola, M., & Královics, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1012718 · Cited by 211 · see citing works
Self-citationETV6: A versatile player in leukemogenesis
Bohlander, S. K. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.01.008 · Cited by 206 · see citing works
AEBP2 as a potential targeting protein for Polycomb Repression Complex PRC2
Kim, H., Kang, K., & Kim, J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp149 · Cited by 192 · see citing works
Walker, E. M., Chang, W. Y., Hunkapiller, J., Cagney, G., Garcha, K., Torchia, J., Krogan, N. J., Reiter, J. F., & Stanford, W. L. (2010) · Cell stem cell · doi:10.1016/j.stem.2009.12.014 · Cited by 188 · see citing works
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Klampfl, T., Harutyunyan, A. S., Berg, T., Gisslinger, B., Schalling, M., Bagienski, K., Olcaydu, D., Passamonti, F., Rumi, E., Pietra, D., et al. (2011) · Blood · doi:10.1182/blood-2011-01-331678 · Cited by 184 · see citing works
Self-citationIDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A. D., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 182 · see citing works
DNMT3A mutations in myeloproliferative neoplasms
Stegelmann, F., Bullinger, L., Schlenk, R. F., Paschka, P., Grießhammer, M., Blersch, C., Kuhn, S. A., Schauer, S., Döhner, H., & Döhner, K. (2011) · Leukemia · doi:10.1038/leu.2011.77 · Cited by 170 · see citing works
Abdel-Wahab, O. I., Pardanani, A. D., Rampal, R. K., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 151 · see citing works
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
Jäger, R., Gisslinger, H., Passamonti, F., Rumi, E., Berg, T., Gisslinger, B., Pietra, D., Harutyunyan, A. S., Klampfl, T., Olcaydu, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.99 · Cited by 137 · see citing works
Self-citationThoennissen, N. H., Krug, U. O., Lee, D. H. T., Kawamata, N., Iwanski, G. B., Lasho, T. L., Weiss, T., Nowak, D., Koren‐Michowitz, M., Kato, M., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235119 · Cited by 122 · see citing works
ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia
Cavé, H., Cacheux, V., Raynaud, S., Brunie, G., Bakkus, M. H. C., Cochaux, P., Preudhomme, C., Laï, J., VILMER, E., & Grandchamp, B. (1997) · Leukemia · doi:10.1038/sj.leu.2400798 · Cited by 104 · see citing works
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
Ding, Y., Harada, Y., Imagawa, J., Kimura, A., & Harada, H. (2009) · Blood · doi:10.1182/blood-2009-06-223982 · Cited by 83 · see citing works
AML transformation in 56 patients with Ph− MPD in two well defined populations
Abdulkarim, K., Girodon, F., Johansson, P. L., Maynadié, M., Kutti, J., Carli, P., Bovet, E., & Andréasson, B. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01163.x · Cited by 79 · see citing works
Lin, P., Jones, D. M., Medeiros, L. J., Chen, W., Vega-Vazquez, F., & Luthra, R. (2006) · American Journal of Clinical Pathology · doi:10.1309/jt5be2l1fgg8p8y6 · Cited by 62 · see citing works
Stegelmann, F., Bullinger, L., Grießhammer, M., Holzmann, K., Habdank, M., Kuhn, S. A., Maile, C., Schauer, S., Döhner, H., & Döhner, K. (2009) · Haematologica · doi:10.3324/haematol.2009.013623 · Cited by 49 · see citing works
Boulay, G., Rosnoblet, C., Guérardel, C., Angrand, P., & Leprince, D. (2011) · Biochemical Journal · doi:10.1042/bj20100944 · Cited by 46 · see citing works
Definitive But Not Primitive Hematopoiesis Is Impaired injumonji Mutant Mice
Kitajima, K., Kojima, M., Nakajima, K., Kondo, S., Hara, T., Miyajima, A., & Takeuchi, T. (1999) · Blood · doi:10.1182/blood.v93.1.87 · Cited by 45 · see citing works
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
Brecqueville, M., Cervera, N., Adélaı̈de, J., Rey, J., Carbuccia, N., Chaffanet, M., Mozziconacci, J., Vey, N., Birnbaum, D., Gelsi‐Boyer, V., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.31 · Cited by 44 · see citing works
Flach, J., Dicker, F., Schnittger, S., Schindela, S., Kohlmann, A., Haferlach, T., Kern, W., & Haferlach, C. (2011) · Leukemia · doi:10.1038/leu.2010.304 · Cited by 41 · see citing works
Taketani, T., Taki, T., Takita, J., Ono, R., Horikoshi, Y., Kaneko, Y., Sako, M., Hanada, R., Hongo, T., & Hayashi, Y. (2002) · Leukemia · doi:10.1038/sj.leu.2402612 · Cited by 24 · see citing works
Novel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN
Thoennissen, N. H., Lasho, T. L., Thoennissen, G. B., Ogawa, S., Tefferi, A., & Koeffler, H. P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22069 · Cited by 23 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic trans- formation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-370.
Cited by
Sorted by citations
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Královics, R. (2016) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 673 · see citing works
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I. V., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.83 · Cited by 428 · see citing works
Interactions between JARID2 and Noncoding RNAs Regulate PRC2 Recruitment to Chromatin
Kaneko, S., Bonasio, R., Saldaña-Meyer, R., Yoshida, T., Son, J., Nishino, K., Umezawa, A., & Reinberg, D. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.012 · Cited by 374 · see citing works
Chromatin repressive complexes in stem cells, development, and cancer
Laugesen, A., & Helin, K. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.006 · Cited by 352 · see citing works
Xie, H., Xu, J., Hsu, J. H.-R., Nguyen, M., Fujiwara, Y., Peng, C., & Orkin, S. H. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.10.001 · Cited by 320 · see citing works
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Wouters, B. J., & Delwel, R. (2015) · Blood · doi:10.1182/blood-2015-07-604512 · Cited by 293 · see citing works
Epigenetic control of adult stem cell function
Avgustinova, A., & Benitah, S. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.76 · Cited by 216 · see citing works
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and CancerPreprint
Laugesen, A., Højfeldt, J. W., & Helin, K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026575 · Cited by 214 · see citing works
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Valencia, A. M., & Kadoch, C. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0258-1 · Cited by 205 · see citing works
Terashima, M., Tange, S., Ishimura, A., & Suzuki, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.750950 · Cited by 199 · see citing works
Caye‐Eude, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, É., Nouri, K., Nakhaei‐Rad, S., Dvorský, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3420 · Cited by 190 · see citing works
Shiozawa, Y., Malcovati, L., Gallì, A., Sato‐Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 172 · see citing works
Self-citationEngaging chromatin: PRC2 structure meets function
Chammas, P., Mocavini, I., & Croce, L. D. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0615-2 · Cited by 138 · see citing works
Norfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544197 · Cited by 126 · see citing works
Self-citationTargeting EZH2 and PRC2 dependence as novel anticancer therapy
Xu, B., Konze, K. D., Jin, J. J., & Wang, G. G. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.001 · Cited by 124 · see citing works
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
Gupta, V. K., Hari, P., & Hoffman, R. (2012) · Blood · doi:10.1182/blood-2012-05-399048 · Cited by 107 · see citing works
Yuan, D., Xu, J., Wang, J., Pan, Y., Fu, J., Bai, Y., Zhang, J., & Shao, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9017 · Cited by 98 · see citing works
Mascarenhas, J. O., Mughal, T. I., & Verstovšek, S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803251511 · Cited by 95 · see citing works
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84 · see citing works
“Mutations in other PRC2 components are rare in myeloid malignancies, but have recently been reported for SUZ12 and EED in MDS (Puda et al., 2012; Score et al., 2012).”
BackgroundDevillier, R., Mas, V. M., Gelsi‐Boyer, V., Demur, C., Murati, A., Corre, J., Prébet, T., Bertoli, S., Brecqueville, M., Arnoulet, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3460 · Cited by 81 · see citing works
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
Greenblatt, S. M., & Nimer, S. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 84 · see citing works
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Feenstra, J. D. M., Puda, A., Malcovati, L., Berg, T., Hofbauer, M., Stukalov, A., Klampfl, T., Harutyunyan, A. S., Gisslinger, H., Gisslinger, B., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23309 · Cited by 78 · see citing works
Self-citationGenetic and epigenetic alterations of myeloproliferative disorders
Feenstra, J. D. M., & Královics, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1235-2 · Cited by 76 · see citing works
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
on behalf of AGIMM investigators, Tenedini, E., Bernardis, I., Artusi, V., Artuso, L., Roncaglia, E., Guglielmelli, P., Pieri, L., Bogani, C., Biamonte, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.302 · Cited by 73 · see citing works
Self-citationRecent advances in the ARID family: focusing on roles in human cancer
Zhao, H., Wei, S., Bi, X., Zhao, J., Huang, Z. K., Li, Z., Zhou, J., Cai, J., & Chen, L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s57023 · Cited by 71 · see citing works
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 67 · see citing works
A microRNA Encoded by Kaposi Sarcoma-Associated Herpesvirus Promotes B-Cell Expansion In Vivo
Dahlke, C., Maul, K., Christalla, T., Walz, N., Schult, P., Stocking, C., & Grundhoff, A. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049435 · Cited by 67 · see citing works
Tange, S., Oktyabri, D., Terashima, M., Ishimura, A., & Suzuki, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115684 · Cited by 64 · see citing works
Celik, H., Koh, W. K., Kramer, A. C., Ostrander, E. L., Mallaney, C., Fisher, D. A. C., Xiang, J., Wilson, W. C., Martens, A., Kothari, A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.008 · Cited by 59 · see citing works
Polycomb complexes in normal and malignant hematopoiesis
Carlo, V. D., Mocavini, I., & Croce, L. D. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201808028 · Cited by 61 · see citing works
Scelfo, A., Piunti, A., & Pasini, D. (2014) · FEBS Journal · doi:10.1111/febs.13112 · Cited by 58 · see citing works
Lessons from next-generation sequencing analysis in hematological malignancies
Braggio, E., Egan, J. B., Fonseca, R., & Stewart, A. K. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.26 · Cited by 57 · see citing works
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
Higgins, A. S., & Shah, M. V. (2020) · Genes · doi:10.3390/genes11070749 · Cited by 50 · see citing works
Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow
Tzankov, A., Hebeda, K. M., Kremer, M., Leguit, R. J., Orazi, A., van der Walt, J. D., & Gianelli, U. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2947-4 · Cited by 49 · see citing works
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 48 · see citing works
Epigenetic regulators and their impact on therapy in acute myeloid leukemia
Pastore, F., & Levine, R. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 50 · see citing works
Targeting epigenetic machinery: Emerging novel allosteric inhibitors
Ye, F., Huang, J. L., Wang, H., Luo, C., & Zhao, K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107406 · Cited by 45 · see citing works
Lei, X., Xu, J., Chang, R., Fěng, F., Zuo, C., & Yang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9733 · Cited by 45 · see citing works
Tsai, C. T., & So, C. W. E. (2016) · Oncogene · doi:10.1038/onc.2016.315 · Cited by 45 · see citing works
Zhang, Q., Agius, S. C., Flanigan, S. F., Uckelmann, M., Levina, V., Owen, B. M., & Davidovich, C. (2021) · Nature Communications · doi:10.1038/s41467-021-24866-3 · Cited by 42 · see citing works
Lorzadeh, A., Romero-Wolf, M., Goel, A., & Jadhav, U. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.036 · Cited by 37 · see citing works
Kanagal‐Shamanna, R., Hodge, J. C., Tucker, T., Shetty, S., Yenamandra, A. K., Dixon‐McIver, A., Bryke, C. R., Huxley, E., Lennon, P. A., Raca, G., et al. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.07.003 · Cited by 34 · see citing works
Interpreting new molecular genetics in myelodysplastic syndromes
Abdel-Wahab, O. I., & Figueroa, M. E. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.56.3798194 · Cited by 33 · see citing works
JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression
Su, C., Deng, T., Shang, Z., & Xiao, Y. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1797-x · Cited by 31 · see citing works
Santini, V., Melnick, A. M., Maciejewski, J. P., Duprez, E., Nervi, C., Cocco, L., Ford, K. G., & Mufti, G. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.004 · Cited by 29 · see citing works
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Ungerstedt, J. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103091 · Cited by 30 · see citing works
Epigenetic Modifiers in Normal and Malignant Hematopoiesis
Haladyna, J. N., Yamauchi, T., Neff, T., & Bernt, K. M. (2015) · Epigenomics · doi:10.2217/epi.14.88 · Cited by 29 · see citing works
Dan, C., Chi, J., & Wang, L. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1009156 · Cited by 27 · see citing works
Iseki, H., Nakachi, Y., Hishida, T., Yamashita-Sugahara, Y., Hirasaki, M., Ueda, A., Tanimoto, Y., Iijima, S., Sugiyama, F., Yagami, K., et al. (2015) · Stem Cells · doi:10.1002/stem.2243 · Cited by 27 · see citing works
Mutations and deletions of PRC2 in prostate cancer
Jain, P., & Croce, L. D. (2016) · BioEssays · doi:10.1002/bies.201500162 · Cited by 25 · see citing works
Mutations in myeloproliferative neoplasms – their significance and clinical use
Schischlik, F., & Královics, R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1380515 · Cited by 23 · see citing works
Zhang, X., Li, J., Yang, Q., Wang, Y., Li, X., Liu, Y., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3773 · Cited by 21 · see citing works
Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN
Paşca, S., Chifotides, H. T., Verstovšek, S., & Bose, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.008 · Cited by 21 · see citing works
Abdel-Wahab, O. I., Pardanani, A. D., Bernard, O., Finazzi, G., Crispino, J. D., Gisslinger, H., Královics, R., Odenike, O. M., Bhalla, K. N., Gupta, V. K., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23169 · Cited by 20 · see citing works
Self-citationFunction of JARID2 in bovines during early embryonic development
Fu, Y., Xu, J., Sun, X.-L., Jiang, H., Han, D., Liu, C., Gao, Y., Yuan, B., & Zhang, J. (2017) · PeerJ · doi:10.7717/peerj.4189 · Cited by 19 · see citing works
Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine
Chetverina, D., Ломаев, Д. В., & Erokhin, M. (2020) · Acta Naturae · doi:10.32607/actanaturae.11090 · Cited by 19 · see citing works
Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia
Xu, H., Wen, Y., Jin, R., & Chen, H. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.975819 · Cited by 17 · see citing works
Genetic Basis of MPN: Beyond JAK2-V617F
Them, N. C. C., & Královics, R. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0184-z · Cited by 17 · see citing works
Bernt, K. M., Hunger, S. P., & Neff, T. (2016) · Frontiers in Pediatrics · doi:10.3389/fped.2016.00049 · Cited by 16 · see citing works
Focus on the epigenome in the myeloproliferative neoplasms
Kim, E. H., & Abdel-Wahab, O. I. (2013) · Hematology · doi:10.1182/asheducation-2013.1.538 · Cited by 15 · see citing works
Easwar, A., & Siddon, A. J. (2021) · Life · doi:10.3390/life11111158 · Cited by 15 · see citing works
Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1microdeletions
Mußotter, T., Kluwe, L., Högel, J., Nguyen, R., Cooper, D. N., Mautner, V., & Kehrer‐Sawatzki, H. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-98 · Cited by 15 · see citing works
Bodmer, A., Menter, T., Juškevičius, D., Arranto, C., Wenzel, F., Dirnhofer, S., & Tzankov, A. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2075-5 · Cited by 15 · see citing works
Olsson, L., Zettermark, S., Biloglav, A., Castor, A., Behrendtz, M., Forestier, E., Paulsson, K. M., & Johansson, B. (2016) · British Journal of Haematology · doi:10.1111/bjh.14056 · Cited by 14 · see citing works
Gong, S., Xu, M. M., Xiang, M., Shan, Y., & Zhang, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00678 · Cited by 14 · see citing works
Heaney, M. L., & Soriano, G. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0154-5 · Cited by 14 · see citing works
Serrano, G., Berastegui, N., Díaz-Mazkiaran, A., García‐Olloqui, P., Rodriguez-Res, C., Huerga-Domínguez, S., Ainciburu, M., Vilas‐Zornoza, A., Martín‐Úriz, P. S., Aguirre‐Ruiz, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49529-x · Cited by 12 · see citing works
Molecular basis and clonal evolution of myeloproliferative neoplasms
Jäger, R., & Královics, R. (2010) · Haematologica · doi:10.3324/haematol.2009.019570 · Cited by 12 · see citing works
Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance
Goleij, P., Heidari, M. M., Tabari, M. A. K., Hadipour, M., Rezaee, A., Javan, A., Sanaye, P. M., Larsen, D. S., Daglia, M., & Khan, H. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01563-8 · Cited by 11 · see citing works
Zhang, L., Zhang, R., Wang, J., Chen, Y., Qiao, C., Shi, Q., Jin, Y., Shen, X., Li, J., & Chen, L. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01314-7 · Cited by 11 · see citing works
Kuang, W., Jiang, W., Chen, Y., Tian, Y., & Liu, Z. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1942711 · Cited by 9 · see citing works
Molecular basis and clonal evolution of myeloproliferative neoplasms
Cleary, C., & Královics, R. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0135 · Cited by 9 · see citing works
Polycomb group proteins – epigenetic repressors with emerging roles in melanocytes and melanoma
Huang, J. M., & Hornyak, T. J. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12341 · Cited by 9 · see citing works
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?
Constantinescu, S. N., & Vainchenker, W. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.553.3800163 · Cited by 8 · see citing works
Epigenetic deregulation in myeloid malignancies
Meldi, K. M., & Figueroa, M. E. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.012 · Cited by 8 · see citing works
Salati, S., Zini, R., Nuzzo, S., Guglielmelli, P., Pennucci, V., Prudente, Z., Ruberti, S., Rontauroli, S., Norfo, R., Bianchi, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29920 · Cited by 7 · see citing works
Self-citationGenetic Impairments of PRC2 Activity in Oncology: Problems and Prospects
Chetverina, D., Ломаев, Д. В., Georgiev, P. G., & Erokhin, M. (2021) · Russian Journal of Genetics · doi:10.1134/s1022795421030042 · Cited by 5 · see citing works
YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells
Noguera, N. I., Travaglini, S., Scalea, S., Catalanotto, C., Reale, A., Zampieri, M., Zaza, A., Ricciardi, M. R., Angelini, D. F., Tafuri, A., et al. (2023) · Cancers · doi:10.3390/cancers15154010 · Cited by 5 · see citing works
Hojjatipour, T., Ajeli, M., Maali, A., & Azad, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104498 · Cited by 5 · see citing works
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms
Rotunno, G., Guglielmelli, P., Biamonte, F., Rumi, E., Cazzola, M., & Vannucchi, A. M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1827-9 · Cited by 4 · see citing works
Self-citationBCR-ABL1 -Negative Chronic Myeloid Neoplasms: An Update on Management Techniques
Vannucchi, A. M., Pieri, L., Susini, M. C., & Guglielmelli, P. (2012) · Future Oncology · doi:10.2217/fon.12.50 · Cited by 3 · see citing works
Self-citationChi, K., Li, Y., Ding, Q.-L., Xu, L. P., Chen, Y., & Wang, X. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1020803 · Cited by 3 · see citing works
Bock, O. (2013) · Journal of Leukemia · doi:10.4172/2329-6917.1000108 · Cited by 3 · see citing works
Gracia-Diaz, C., Perdomo, J. E., Khan, M. E., Disanza, B., Cajka, G. G., Lei, S., Gagne, A. L., Maguire, J. A., Roulé, T., Shalem, O., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.26.546614 · Cited by 2 · see citing works
Chi, K., Li, Y., Xu, L., & Wang, X. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1292357 · Cited by 2 · see citing works
Pavlović, S., & Tos̆ić, N. (2019) · Europeanization and globalization · doi:10.1007/978-3-030-16465-2_28 · Cited by 1 · see citing works
Guglielmelli, P., Rotunno, G., Pacilli, A., & Vannucchi, A. M. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0285-y · Cited by 1 · see citing works
Self-citationIntegrated Bioinformatics And Experimental Validation Reveal The Role Of Jarid2 In Ovarian Cancer
Huang, D., Wang, R., Tian, L., & Wang, H. (2023) · Epigenomics · doi:10.2217/epi-2023-0128 · Cited by 1 · see citing works
The Role of Polycomb Group Proteins in Hematopoietic Stem Cell (HSC) Self-Renewal and Leukemogenesis
van den Boom, V., Schepers, H., Brouwers-Vos, A. Z., & Schuringa, J. J. (2014) · Epigenetics and human health · doi:10.1007/978-3-642-45198-0_6
Vannucchi, A. M., & Guglielmelli, P. (2012)
Self-citationGuo, H., Chu, Y., & Yuan, W. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.02.021
Can molecular insights guide treatment of AML evolved from MPNs?
Crispino, J. D., & Rampal, R. K. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101323
Gurun, B., Tyner, J. W., Demir, E., Druker, B. J., & Spellman, P. T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.17.541249
Serrano, G., Berastegui, N., Díaz-Mazkiaran, A., García‐Olloqui, P., Huerga-Domínguez, S., Piérola, A. A., Ainciburu, M., Vilas‐Zornoza, A., Martin, P. S., Aguirre‐Ruiz, P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.19.562875
Chi, K., & Song, L. (2025) · Leukemia Research Reports · doi:10.1016/j.lrr.2025.100542
Han, W., Bjeije, H., Celik, H., Rettig, M. P., Issa, N., Young, A. L., Li, Y., Raj, I. X., Zhang, C. R., Krishnan, A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019220
Zhang, L., Zhang, R., Wang, J., Chen, Y., Qiao, C., Shi, Q., Jin, Y., Shen, X., Li, J., & Chen, L. (2022) · Figshare · doi:10.6084/m9.figshare.20367145
Zhang, L., Zhang, R., Wang, J., Chen, Y., Qiao, C., Shi, Q., Jin, Y., Shen, X., Li, J., & Chen, L. (2022) · Figshare · doi:10.6084/m9.figshare.20367148
- Authors
- Puda, A., Milosevic, J. D., Berg, T., Klampfl, T., Harutyunyan, A. S., Gisslinger, B., Rumi, E., Pietra, D., Malcovati, L., Elena, C., Doubek, M., Steurer, M., Tosic, N., Pavlovic, S., Guglielmelli, P., Pieri, L., Vannucchi, A. M., Gisslinger, H., Cazzola, M., & Kralovics, R.
- Affiliations
- Austrian Academy of Sciences (AT)
- Medical University of Vienna (AT)
- University of Pavia (IT)
- Masaryk University (CZ)
- Innsbruck Medical University (AT)
- University of Florence (IT)
- ORCID
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2011-12-21
- Volume
- 87
- Issue
- 3
- Pages
- 245-250
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2059130068
- Cited by
- 105
- References
- 45
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 12 · 2015: 13 · 2014: 11 · 2013: 12 · 2012: 11
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IMAGINE - Repository of the Institute of molecular genetics and genetic engineering (University of Belgrade) (submittedVersion, cc-by)
- Funders
- MPN Research Foundation
- Austrian Science Fund
- Fondazione Cariplo
- Associazione Italiana per la Ricerca sul Cancro (5X 1000)
- Regione Lombardia
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Keywords
- JARID2, leukemic transformation, myeloproliferative neoplasms, myelodysplastic syndrome, acute myeloid leukemia, polycomb repressive complex 2, tumor suppressor, EZH2, AEBP2, SUZ12, ETV6, neurofibromatosis type 1, somatic mutations, chromosomal deletion
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Acute Disease, Aged, Carrier Proteins, Cell Transformation, Neoplastic, Chromosome Aberrations, Chromosome Deletion, Chromosome Mapping, Chromosomes, Human, Pair 6, DNA-Binding Proteins, Female, Genotype, Humans, Leukemia, Myeloid, Male, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Proteins, Nerve Tissue Proteins, Nuclear Proteins, Repressor Proteins, Transcription Factors, Genes, Tumor Suppressor, Sequence Analysis, DNA, Disease Progression, Oligonucleotide Array Sequence Analysis, Tumor Suppressor Proteins, Polycomb-Group Proteins, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
